Akari Therapeutics Plc Uncategorized Contracts & Agreements
14 Contracts & Agreements
- Amendment to Interim Chief Executive Officer Agreement, between Akari Therapeutics, Plc and Samir R. Patel, M.D., dated as of September 16, 2024 (Filed With SEC on September 18, 2024)
- Amendment to Interim Chief Executive Officer Agreement, dated as of September 13, 2024, by and between the Registrant and Samir Patel, M.D (Filed With SEC on September 13, 2024)
- Interim Chief Executive Officer Agreement, dated as of May 31, 2024, by and between the Company and Samir Patel, M.D (Filed With SEC on June 5, 2024)
- Stock Option Agreement between the Company and Wendy F. DiCicco dated July 17, 2023 (Filed With SEC on March 29, 2024)
- Amendment No. 1 to Consulting Agreement between the Company and Wendy DiCicco dated September 1, 2023 (Filed With SEC on March 29, 2024)
- Consulting Agreement between the Company and Wendy F. DiCicco dated January 15, 2024 (Filed With SEC on March 29, 2024)
- Consulting Agreement between the Company and Wendy DiCicco dated July 17, 2023 (Filed With SEC on March 29, 2024)
- Restricted Stock Unit Agreement between the Company and Rachelle Jacques dated June 1, 2023 (Filed With SEC on March 29, 2024)
- Form of Restricted Stock Unit Agreement Granted Under the 2023 Equity Incentive Plan (Filed With SEC on March 29, 2024)
- Stock Option Agreement between the Company and Rachelle Jacques dated March 28, 2023 (Filed With SEC on March 29, 2024)
- Form of ISO/NQ Stock Option Agreement Granted Under the 2023 Equity Incentive Plan (Filed With SEC on March 29, 2024)
- Description of the Akari Therapeutics Plc Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 29, 2024)
- AKARI THERAPEUTICS PLC and Clive richardson (Filed With SEC on September 22, 2015)
- Schedule 12 (Filed With SEC on July 13, 2015)